Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,460,879
  • Shares Outstanding, K 107,650
  • Annual Sales, $ 365,980 K
  • Annual Income, $ 112,510 K
  • 60-Month Beta 0.59
  • Price/Sales 7.07
  • Price/Cash Flow 22.97
  • Price/Book 5.23
Trade CORT with:

Options Overview Details

View History
  • Implied Volatility 66.58% ( +7.21%)
  • Historical Volatility 32.03%
  • IV Percentile 98%
  • IV Rank 85.95%
  • IV High 72.59% on 01/13/23
  • IV Low 29.84% on 11/22/22
  • Put/Call Vol Ratio 0.17
  • Today's Volume 48
  • Volume Avg (30-Day) 393
  • Put/Call OI Ratio 2.42
  • Today's Open Interest 8,173
  • Open Int (30-Day) 9,354

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.15
  • Number of Estimates 4
  • High Estimate 0.27
  • Low Estimate 0.05
  • Prior Year 0.26
  • Growth Rate Est. (year over year) -42.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.78 +21.03%
on 01/05/23
24.27 -1.36%
on 01/23/23
+3.63 (+17.87%)
since 12/30/22
3-Month
19.59 +22.21%
on 12/16/22
30.14 -20.57%
on 11/02/22
-6.02 (-20.09%)
since 11/01/22
52-Week
17.19 +39.27%
on 05/11/22
30.14 -20.57%
on 11/02/22
+5.13 (+27.27%)
since 02/01/22

Most Recent Stories

More News
2 Under-The-Radar Stocks to Buy Now Before Wall Street Catches On

With the combination of still-higher rates and widespread recessionary concerns, the stock market will likely stay under pressure for the near term. Therefore, it could be wise to buy fundamentally strong...

ARCO : 8.52 (+0.24%)
CORT : 23.94 (+4.72%)
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

MRK : 106.98 (-0.40%)
ALT : 13.78 (+1.03%)
CORT : 23.94 (+4.72%)
ASRT : 4.03 (-1.95%)
2 Biotech Stocks Under $100 to Buy Now

The biotech industry flourished amid the pandemic, and lucrative federal investments are expected to drive further growth in the sector. Moreover, amid evolving variants of Coronavirus, the biotech industry...

CORT : 23.94 (+4.72%)
GILD : 84.00 (+0.07%)
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

DRRX : 6.22 (-4.45%)
CORT : 23.94 (+4.72%)
NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

CORT : 23.94 (+4.72%)
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).

CORT : 23.94 (+4.72%)
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CORT : 23.94 (+4.72%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”)...

CORT : 23.94 (+4.72%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”)...

CORT : 23.94 (+4.72%)
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

MRK : 106.98 (-0.40%)
UTHR : 259.99 (-1.21%)
CORT : 23.94 (+4.72%)
CPRX : 15.31 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 25.98
2nd Resistance Point 25.05
1st Resistance Point 24.50
Last Price 23.94
1st Support Level 23.02
2nd Support Level 22.09
3rd Support Level 21.54

See More

52-Week High 30.14
Fibonacci 61.8% 25.19
Last Price 23.94
Fibonacci 50% 23.67
Fibonacci 38.2% 22.14
52-Week Low 17.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar